2-[4-[2-(3,5-dimethoxy-4-methylbenzoyl)-5-phenylpentyl]phenyl]acetic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 2-[4-[2-(3,5-dimethoxy-4-methylbenzoyl)-5-phenylpentyl]phenyl]acetic acid
• 英文别名: (4-(2-(3,5-dimethoxy-4-methylphenylcarbonyl)-5-phenylpentyl)phenyl)acetic acid
• 化学式: C₂₉H₃₂O₅
• 分子量: 460.57
• InChiKey: DMZSLZUGXDWLMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[4-[2-(3,5-dimethoxy-4-methylbenzoyl)-5-phenylpentyl]phenyl]acetic acid 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 1.0h， 生成 (4-{2-[(3,5-dimethoxy-4-methylphenyl)(hydroxy)methyl]-5-phenylpentyl}phenyl)acetic acid
  参考文献：
  名称：

  LPA RECEPTOR ANTAGONISTS

  摘要：

  公开号：

  EP1553075B1
• 作为产物：
  描述：

  1-氯-3-苯基丙烷 在 五甲基二乙烯三胺 、 magnesium 、 sodium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.83h， 生成 2-[4-[2-(3,5-dimethoxy-4-methylbenzoyl)-5-phenylpentyl]phenyl]acetic acid
  参考文献：
  名称：

  Discovery of a Slow Tight Binding LPA1 Antagonist (ONO-0300302) for the Treatment of Benign Prostatic Hyperplasia

  摘要：

  Scaffold hopping from the amide group of lead compound ONO 7300243 (1) to a secondary alcohol successfully gave a novel chemotype lysophosphatidic acid receptor 1 (LPA(1)) antagonist 4. Wash-out experiments using rat isolated urethra showed that compound 4 possesses a tight binding feature to the LPAI receptor. Further modification of two phenyl groups of 1 to pyrrole and an indane moiety afforded an optimized compound ONO-0300302 (19). Despite its high i.v. clearance, 19 inhibited significantly an LPA-induced increase of intraurethral pressure (IUP) in rat (3 mg/kg, p.o.) and dog (1 mg/kg, p.o.) over 12 h. Binding experiments with [H-3]-ONO-0300302 suggest that the observed long duration action is because of the slow tight binding character of 19.

  DOI：

  10.1021/acsmedchemlett.7b00383

文献信息

• LPA Receptor Antagonists
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2565178A1

  公开（公告）日：2013-03-06

  A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation / immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).

  通式(I)的化合物： (其中符号如描述中所定义），或其无毒盐 该化合物参与 LPA 受体的结合和拮抗作用，因此可用于预防和/或治疗泌尿系统疾病（症状为前列腺肥大或神经源性膀胱功能障碍疾病、脊髓肿瘤、核疝、椎管狭窄或糖尿病、下尿路闭塞症、下尿路炎症、多尿）、癌症相关疾病（实体瘤、实体瘤转移、血管纤维瘤、骨髓瘤、多发性骨髓瘤卡波西肉瘤、白血病和癌浸润转变）、增殖性疾病（血管异常生成障碍、动脉阻塞和肺纤维化）、炎症/免疫系统疾病（银屑病、肾病、肝炎和肺炎症状）、分泌功能障碍引起的疾病（Sjogren 综合症）、与脑有关的疾病（脑梗塞、脑中风、脑或周围神经病）或慢性疾病（慢性哮喘、肾小球肾炎、肥胖症、前列腺增生、动脉硬化过程引起的疾病、风湿病或特应性皮炎）。
• Lpa receptor antagonist
  申请人：Terakado Masahiko

  公开号：US20060148830A1

  公开（公告）日：2006-07-06

  A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
• LPA RECEPTOR ANTAGONIST
  申请人：Terakado Masahiko

  公开号：US20080293764A1

  公开（公告）日：2008-11-27

  A compound of the general formula (I): (wherein the symbols are as defined in the description), or a non-toxic salt thereof. This compound engages in LPA receptor bonding and antagonism and hence is useful in the prevention and/or treatment of urinary system disease (symptom with prostatic hypertrophy or neurogenic bladder dysfunction disease, symptom to be caused by spinal cord neoplasm, nucleous hernia, spinal canal stenosis or diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, polyuria), carcinoma-associated disease (solid tumor, solid tumor metastasis, angiofibroma, myeloma, multiple myeloma, Kaposi's sarcoma, leucemia and carcinomatous infiltration transition), proliferative disease (disorder with aberrant angiogenesis, artery obstruction and pulmonary fibrosis), inflammation/immune system disease (psoriasis, nephropathy, hepatitis and pneumonitis symptom), disease caused by secretory dysfunction (Sjogren syndrome), brain-related disease (brain infarction, cerebral apoplexy and brain or peripheral neuropathy) or chronic disease (chronic asthma, glomerulonephritis, obesity, prostate hyperplasia, diseases caused by arteriosclerosis process, rheumatism or atopic dermatitis).
• US7820682B2
  申请人：——

  公开号：US7820682B2

  公开（公告）日：2010-10-26
• US8124645B2
  申请人：——

  公开号：US8124645B2

  公开（公告）日：2012-02-28